| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50d7823b0feadc69a518d95f9deb2b4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d045b47408c6fdbd4c21edef23344960
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_105c7d16d9e3e3b3f7921e0684e05ed3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ecbfebc5cce247290222ec8a9da8ab8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2caaba601fd6460c7b37706d920d42e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebeaf7f91092dc659522e3283da11023 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2017-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00bb6ed7458a5d6e082166bddccd9fed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e74c98bd1bcce0018b0d90d6679431a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_224355445fa114acf6625ed917a25f7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f6b8241a25e3f12d0b20cdbda92d138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70220682465b86dfe2f9d48e15dfaae6 |
| publicationDate |
2020-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10729739-B2 |
| titleOfInvention |
Methods of treating prostate cancer with GnRH antagonist |
| abstract |
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE49353-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11766468-B2 |
| priorityDate |
2008-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |